Selexys' sickle sale

Selexys A round by MPM comes with a Novartis option to buy hematology company

Selexys' sickle sale

MPM Capital is betting that veterans from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) can turn the firm's investment in hematology play Selexys Pharmaceuticals Corp. into a takeout within three years.

Last week, Selexys raised $23 million in a

Read the full 378 word article

How to gain access

Continue reading with a
two-week free trial.